USPTO serial 79444790
GUIDERX BY GOJITECH
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- STRUCK, ROBERT J
- Law office
- TMEG LAW OFFICE 109
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with GUIDERX BY GOJITECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for accessing, browsing and searching databases containing clinical research data in the field of cannabinoid-based pharmaceuticals and therapy; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for administering insurance coverage; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for customized searching and filtering of catalogs and formularies of the pharmaceutical products of others; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for managing insurance policies; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for processing insurance claims; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for providing information about cannabinoid-based pharmaceuticals and therapy; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for providing information about insurance policies and rates; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for searching structured and unstructured data for healthcare analytics; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for the management and electronic delivery of insurance documents and insurance claims information; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for use in customer relationship management (CRM); providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for use in the analysis and evaluation of the products of others to assure compliance with industry standards; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) to allow users to track and analyze consumer consumption of cannabinoid-based pharmaceuticals for medical purposes; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) to automate workflows in the field of healthcare; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for facilitating the interoperability and secure exchange of healthcare information; providing non-downloadable artificial intelligence software, computer software, platform as a service (PaaS), and software as a service (SaaS) for digital health analytics; cannabinoid product evaluation; data automation and collection of clinical data from pharmacy-led patient care programs to support evaluation, analysis, and research; data automation and data collection using software to evaluate, analyze, collect clinical research data in the field of cannabinoid-based pharmaceuticals and therapy; providing medical and scientific research information in the field of cannabinoid-based pharmaceuticals and therapy. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 9, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 24, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 24, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 6, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 5, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 28, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 26, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 26, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 26, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |